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SUMMARY
Fatty acid b-oxidation (FAO), the breakdown of lipids, is a metabolic pathway used by various stem cells. FAO levels are generally high
during quiescence and downregulated with proliferation. The endogenous metabolite malonyl-CoA modulates lipid metabolism as a
reversible FAO inhibitor and as a substrate for de novo lipogenesis. Here we assessed whether malonyl-CoA can be exploited to steer
the behavior of hematopoietic stem/progenitor cells (HSPCs), quiescent stem cells of clinical relevance. Treatment of mouse HSPCs
in vitro with malonyl-CoA increases HSPC numbers compared with nontreated controls and ameliorates blood reconstitution capacity
when transplanted in vivo, mainly through enhanced lymphoid reconstitution. Similarly, humanHSPC numbers also increase uponma-
lonyl-CoA treatment in vitro. These data corroborate that lipid metabolism can be targeted to direct cell fate and stem cell proliferation.
Physiological modulation of metabolic pathways, rather than genetic or pharmacological inhibition, provides unique perspectives for
stem cell manipulations in health and disease.
INTRODUCTION
Cellularmetabolismhas emerged as a keymechanism regu-
lating stem cell quiescence and proliferation (Chandel
et al., 2016; Ito and Suda, 2014) and lipidmetabolism plays
an important role in this regulation. Whereas the build-up
of lipids via de novo lipogenesis promotes proliferation of
stem cells (Knobloch et al., 2013; Wang et al., 2017), the
breakdown of lipids via fatty acid b-oxidation (FAO) is
crucial for themaintenance of adult stem cells, such as neu-
ral stem cells (Knobloch et al., 2017; Stoll et al., 2015), mus-
cle satellite cells (Ryall et al., 2015), intestinal stem cells
(Mihaylova et al., 2018), and hematopoietic stem cells
(Ito et al., 2012), indicating conserved regulatory mecha-
nisms of stem cell activity through metabolism.
The role of FAO in stem cell maintenance has been estab-
lished by genetic manipulation of FAO enzymes, such as
the peroxisome-proliferator activated receptors (PPARs) or
carnitine palmitoyl transferase 1 (Cpt1), or via pharmaco-
logical inhibitors and activators of FAO. Although these
approaches are well-suited to test the importance of ameta-
bolic pathway, they may not reflect the changes that occur
under physiological conditions. For instance, cells aremore
likely shifting between differentmetabolic pathways rather
than switching a pathway on or off completely. A shift
rather than switch concept is in line with recent single-
cell RNA sequencing, data suggesting transitions from
one state to the other rather than clear stepwise progres-
sions (Macaulay et al., 2016; Shin et al., 2015).
We have shown that shifting lipid metabolism using ma-
lonyl-CoA, the endogenous metabolite that reversibly in-
hibits Cpt1a/FAO (Foster, 2012) and serves as a building
block for de novo lipogenesis, alters the behavior of quiescent
neural stem/progenitor cells (NSPCs). The addition of ma-
lonyl-CoA to cultured quiescent NSPCs is sufficient to
induce proliferation (Knobloch et al., 2017). Here we ad-
dressed whether malonyl-CoA has similar effects on HSPCs.
Increasing the numbers of HSPCs in vitro, without losing
stem cell capacity, is of clinical interest, specifically for um-
bilical cord blood (Kiernan et al., 2017) and for expansion
of HSPCs after genetic modifications, as required for gene
therapy approaches (Morgan et al., 2017). In addition, as
HSPC function is compromised with aging (Kovtonyuk
et al., 2016), increasing HSPC function in the aging context
is of great interest. Previously, Ito and colleagues had shown
the importance of FAO for HSPC maintenance, such that a
complete block of FAO led to HSPC exhaustion (Ito et al.,
2012). Interestingly, they noted that this block of FAO led
initially to a short-term expansion of HSPCs. Given previous
data on quiescence exit upon FAO modulation in NSPCs
(Knobloch et al., 2017), we thus rationalized that modu-
lating lipidmetabolism throughmalonyl-CoA could expand
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HSPCswithout leading to exhaustion.We therefore cultured
HSPCs from young and old mice and human cord blood
with or without malonyl-CoA in vitro and analyzed their
behavior.
RESULTS
HSPCs Show High Expression of Genes Involved in
FAO
We first measured the expression of key FAO genes by qRT-
PCR in three different cell populations derived from the
bone marrow (BM): an HSPCs enriched population (Lin-cK-
it+Sca1+ cells, LKS cells), an intermediate population (lineage
negative cells without LKS, Lin w/o LKS) and a population
consisting of differentiated progeny (lineage positive cell
population, Lin+ cells) separated by flow cytometry (Fig-
ure S1A). Carnitine palmitoyltransferase 1a (Cpt1a), a key
player in FAO as well as other FAO enzymes and regulators
were highly upregulated in LKS cells compared with Lin+
cells (Figure 1A), suggesting that FAO is a pathway specif-
ically important in HSPCs. These findings are in line with
previous findings showing an important role for FAO and
Ppar-d in HSPCmaintenance (Ito et al., 2012).
Given the high expression of Cpt1a in the LKS popula-
tion, we asked whether Cpt1a could be used as an HSPC
specific marker. We used a reporter mouse expressing GFP
under the Cpt1a promoter (Cpt1a-GFP, Gong et al.,
2003), isolating the same three cell populations and
comparing them with wild-type cells. Indeed, a clear GFP
signal was detected in cells from Cpt1a-GFP mice, highest
in the LKS population followed by Lin w/o LKS and Lin+
(Figure 1B), confirming the gene expression data. We
next subdivided the LKS population into five subgroups
based on the expression of the surface markers CD150,
CD48, and CD34 (Kiel et al., 2005; Oguro et al., 2013):
Long-term (LT)-/short-term (ST)-HSCs are defined as LKS
CD150+CD48CD34 or +, two closely related progenitors
termed HPC-1/HPC-2 as LKS CD150 or + CD48+ and
multipotent progenitors (MPPs) as LKS CD150CD48
(Figure S1B). However, all these subgroups of the LKS pop-
ulation showed equally high levels of GFP expression (Fig-
ure S1C). Thus, usingCpt1a-GFPmice, a further distinction
between these purified populations within the LKS popula-
tion was not possible.
Malonyl-CoA Addition In Vitro Alters HSPC Behavior
We next asked whether modulation of FAOmay alter HSPC
behavior. Themetabolitemalonyl-CoA acts at the same time
as the endogenous inhibitor of Cpt1a/FAO and as a rate-
limiting substrate for de novo lipogenesis (Figure 1C),
providing an endogenous mechanism to balance the build-
up and breakdown of lipids within a cell (Foster, 2012).
Thus, increasing the levels of malonyl-CoA provides an
experimental opportunity to manipulate lipid metabolism.
In line with previous results (Knobloch et al., 2017), we
further validated malonyl-CoA uptake in NSPCs (Figures
S1D–S1G). Taken together, these data, established inNSPCs,
suggest that extracellular malonyl-CoA can be taken up and
that it modulates FAO, although in amuchmilder way than
pharmacological FAO inhibitors such as Etomoxir.
Therefore, we tested the effect ofmalonyl-CoA on purified
ST- and LT-HSCs, using two different doses (5 and 50 mM)
over 7 days in culture. Proliferation kinetics were assessed
through analysis of brightfield images. Both ST-HSCs and
LT-HSCs reacted to malonyl-CoA with increased numbers
(Figures S2A–S2J). Due to observed changes in both HSC
populations, we next tested the effect of malonyl-CoA on
a population comprising LT-, ST-HSCs and progenitor cells,
namely LKS cells. We cultured freshly isolated LKS cells
in vitro with or without 5, 50, or 100 mM malonyl-CoA (Fig-
ure S2K); 100 mM resulted in the overall highest cell number
and was used for all following experiments. After 7 days in
Figure 1. FAO Is High in HSPCs and Exposure to Malonyl-CoA Alters HSPC Behavior In Vitro
(A) mRNA expression (fold change ±SEM) of key FAO genes is upregulated in freshly isolated LKS cells compared with an intermediate cell
population (Lin w/o LKS) and differentiated progeny (Lin+). Shown are carnitine palmitoyl transferase 1a (Cpt1a), long-chain acyl-CoA
dehydrogenase (Acadl), very long-chain acyl-CoA dehydrogenase (Acadvl), peroxisome proliferator-activated receptor beta/delta (Ppard)
and the peroxisome proliferator-activated receptor gamma coactivator 1-alpha (Ppargc1a). (n = 3, individual wells per condition) *p <
0.05; **p < 0.01; ***p < 0.001.
(B) Representative flow cytometry plots and GFP histograms show Cpt1a-GFP levels highest in the LKS population followed by Lin w/o LKS
and Lin+ populations.
(C) Scheme depicting the dual function of malonyl-CoA as an endogenous Cpt1a inhibitor and a substrate of de novo lipogenesis.
(D) Schematic outline of the isolation, cultivation, and analysis of LKS cells with or without 100 mM malonyl-CoA.
(E) Surface marker expression of culture LKS cells was analyzed by flow cytometry.
(F) Quantification of the flow cytometry analysis. Total number of cells were normalized to the median of the corresponding control
condition. Malonyl-CoA expanded the number of LKS cells with an increase in all the stem cell sub-populations. Statistical analysis was
done including technical replicates by using nonparametric Mann-Whitney test (n = 7, individual wells per condition, two independent
experiments, cells isolated from 2 3 6 pooled mice). *p < 0.05; **p < 0.01; ***p < 0.001. The increase in LKS cells upon malonyl-CoA
exposure was also observed in several independent experiments with a different experimental setup, see Figures 3B and S2K.
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culture we harvested the entire progeny of cultured LKS and
performed surfacemarker analysis andRNA sequencing (Fig-
ures 1D and S2L). Malonyl-CoA addition significantly
increased the total number of cells with LKS surface marker
characteristics, without a change in the total number of live
cells and Lin cells, nor a change in the percentage of Lin
cells (Figures 1E and 1F). This increase was due to an
increased total number of cells in all stem/progenitor sub-
populations (HPC-1, HPC-2, MPPs, ST-HSCs, LT-HSCs), sug-
gesting that the manipulation of lipid metabolism with the
endogenous metabolite malonyl-CoA increases the total
number of HSPCs in vitro (Figure 1F).
RNA sequencing after 7 days in culture (Figure 1D) re-
vealed only small changes in gene expression with ma-
lonyl-CoA (123 genes); however, hierarchical clustering
and heatmap display of these 123 genes (Figures 2A and
2B) revealed a clear separation of the HSPCs according to
the treatment. Surprisingly, gene ontology (GO) enrich-
ment analysis showed a majority of GO terms involved in
immune system processes (Figure 2C), suggesting that
exposure to malonyl-CoA might also influence HSPC fate.
Malonyl-CoATreatment Increases HSPC Functionality
In Vivo, Mainly by Enhancing Lymphoid
Differentiation Potential
Next, we evaluated whether malonyl-CoA leads to
enhanced HSPC maintenance and function in vivo. We
transplanted the progeny of LKS cells cultured in the pres-
ence or absence of 100 mM malonyl-CoA for 7 days into
lethally irradiated mice, and assessed their contribution
to the myeloid and lymphoid lineage. Cultured LKS cells
(with or without malonyl-CoA) were co-transplanted
with freshly isolated BMcells in lethally irradiated recipient
animals and we used congenic markers to distinguish the
different cell sources (donor CD45.1, competitor CD45.1/
2, recipient CD45.2) (Figure S3A). Blood composition was
assessed at the indicated time points by flow cytometry
(Figures 2D, S3A, and S3B). LKS cells exposed in vitro to ma-
lonyl-CoA showed a higher total engraftment potential
compared with control LKS grown without malonyl-CoA
(Figure 2E). Interestingly, primarily the reconstitution of
the lymphoid lineage was significantly increased, while
the myeloid lineage showed only a slight, nonsignificant
increase (Figure 2E). BM analysis of the primary recipients
27-weeks post transplantation confirmed the increased
contribution of malonyl-CoA–treated LKS cells to the
lymphoid lineage (Figure 2F). Secondary recipients, who
received BM from primary recipients injected with ma-
lonyl-CoA–treated LKS (Figure S3C), showed a slight in-
crease in the overall total long-term repopulation capacity
of the initial donor cells, primarily due to better lymphoid
reconstitution (Figure S3D); however, the differences were
not statistically significant.
In summary, malonyl-CoA-treated LKS cells engrafted
overall better than control LKS and showed the capability
to sustain long-term blood production in primary recipient
mice. The observed increase in the reconstituted lymphoid
population suggests that malonyl-CoA might lead to a
biased fate preference toward the lymphoid lineage. The
result thatmalonyl-CoA–treated LKS cells were slightly bet-
ter than nontreated LKS cells in the secondary transplanta-
tion indicates that a modulation of lipid metabolism with
malonyl-CoA does not lead to HSPC exhaustion.
Several Cell Types of the Lymphoid Lineage Are
Increased upon Malonyl-CoA Treatment
To determine whether there is a similar bias toward the
lymphoid fate in vitro, we performed high-dimensional
flow cytometry on LKS progeny after 7 days in culture with
malonyl-CoA, using 21 different surface markers (Figure 3A,
Figures S4A and S4B). In addition to the increased number of
LKS cells upon malonyl-CoA treatment (Figures 3B and 1F),
we found that also lymphoid progenitors such as multipo-
tent progenitor population 4 (MPP4s, similar to the HPC-1
population, Pietras et al., 2015) and common lymphoid pro-
genitors (CLPs) were upregulated. Conversely, numbers of
commonmyeloid progenitors (CMPs) were not altered (Fig-
ure 3B). The shift toward enhanced lymphoid commitment
was also evident in further differentiatedpopulations suchas
pre B cells, natural killer T (NKT) cells, and Tcells (CD3+, but
CD4 and CD8), which were all significantly upregulated
with malonyl-CoA compared with control LKS cells (Fig-
ure3C). Incontrast,myeloidprogenitors includingmegakar-
yocyte/erythrocyte progenitors (MEPs), granulocyte/mono-
cyte progenitors (GMPs), granulocyte progenitors (GPs),
commonmonocyte progenitors (cMOPs), commonDCpro-
genitors (CDPs), andmonocyte-DCprogenitors (MDPs)were
not affectedbymalonyl-CoA (Figure S4C), suggestinga selec-
tive differentiation toward the lymphoid lineage through
manipulation of lipid metabolism. However, neutrophils
were also significantly increasedwithmalonyl-CoA, suggest-
ing an independent action on the survival/proliferation of
more mature populations (Figure S4C).
Taken together, this analysis confirmed a lymphoid bias
upon malonyl-CoA treatment, similar to the results seen
with in vivo transplantation (Figure 2E).
HSPCs From Aged Mice Remain Responsive to
Malonyl-CoA Treatment
Agedmicehave a strong bias towardmyeloid lineage output,
with negative consequences for immune function (Kovto-
nyuk et al., 2016). By using high-dimensional flow cytome-
try, we asked whether HSPCs from old mice remain respon-
sive to malonyl-CoA (Figure 3D) with a similar lymphoid
fate shift as seen in HSPCs from young mice (Figures 3B
and 3C). The number of LKS cells from old mice increased
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Figure 2. Malonyl-CoA Treatment Increases HSPC Functionality In Vivo, Primarily by Enhancing Lymphoid Differentiation Potential
(A) RNA sequencing revealed a hierarchical clustering into the two treatment groups, based on the 123 most differentially expressed
genes.
(B) Heatmap representation.
(C) Gene ontology (GO) analysis of changed genes points toward increased immune system processes.
(D) Schematic outline of the primary transplantation set up.
(E) Blood analysis of transplanted mice by flow cytometry at different time points (4, 8, 12, 16, 20, 24 weeks posttransplant). Graphs
display the percentage of CD45.1 cells among total cells. Statistical analysis is done with two-way ANOVA followed by Holm-Sidak’s
multiple comparison test (Ctrl n = 7, malonyl-CoA n = 8, number of mice per condition) *p < 0.05.
(F) Flow cytometry analysis of BM chimerism 27 weeks posttransplantation. Malonyl-CoA–treated LKS in the BM showed a significant
increase in the engraftment in the total and lymphoid lineage, while the myeloid lineage was not significantly different. Statistical
analysis was done using nonparametric Mann-Whitney test (Ctrl n = 7, malonyl-CoA n = 8, number of mice per condition). *p < 0.05.
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significantly upon malonyl-CoA treatment (Figures 3E and
S4E), suggesting that aged HSPCs remain indeed responsive.
The lymphoid-biased shift in progenitor populations (MPP4
and CLPs) was also seen (Figures 3E and S4E). However, also
CMPs were increased upon malonyl-CoA treatment (Fig-
ure 3E). The more differentiated lymphoid populations
such as the pre-B cells andB cells showed a slight but nonsig-



















































































































































































































































































































































































Figure 3. High-Dimensional Flow Cytome-
try Analysis Reveals Increased Lymphoid
Populations Upon Malonyl-CoA Treatment
(A) Schematic overview of the lymphoid and
myeloid hierarchies.
(B) Quantification by flow cytometry of the
different progenitor populations, normalized
to the median of the according control con-
dition. This analysis revealed an increase in
LKS cells upon culture with malonyl-CoA, as
well as an increase in lymphoid progenitors
(p = 0.057 for MPP4, p = 0.08 for CLPs),
whereas myeloid-primed progenitors were
not significantly altered.
(C) Analysis of differentiated lymphoid pop-
ulations shows a significant increase in pre-B
cells, NKT cells, and T cells. Statistical anal-
ysis was done including technical replicates
using nonparametric Mann-Whitney test (n =
9, individual wells per condition, two inde-
pendent experiments, cells isolated from 3 to
5 pooled mice respectively). *p < 0.05; **p <
0.01; ***p < 0.001.
(D) Schematic illustration of the changes in
hematopoiesis between young and old mice.
(E) Quantification by flow cytometry of
cultured LKS cells isolated from 2-year-old
mice shows a significant increase in LKS cells
upon culture with malonyl-CoA , as well as an
increase in MPP4 progenitors and CLPs (p =
0.061). However, also myeloid-primed pro-
genitors were significantly altered.
(F) Analysis of differentiated lymphoid pop-
ulations show a significant increase in NKT
and T cells after culture of old LKS cells with
malonyl-CoA. Statistical analysis was done
including technical replicates using
nonparametric Mann-Whitney test (Ctrl n =
11, malonyl-CoA n = 10, individual wells, two
independent experiments, cells isolated from
2 to 4 pooled mice respectively). *p < 0.05;
**p < 0.01; ***p < 0.001. The increase in LKS
cells from old mice upon malonyl-CoA expo-
sure was also observed in a third independent
experiment with a less elaborate antibody
panel, see Figure S4E.
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were significantly increased comparedwith controls, similar
to young cells (Figure 3F). Committed myeloid progenitors
didnot changewithmalonyl-CoA (Figure S4D). Intriguingly,
these data suggest that the lymphoid potential in aged mice
can be increased with metabolic alteration and further cor-
roborates the increase in the number of LKS cells upon ma-
lonyl-CoA exposure.
Malonyl-CoA Treatment Increases the Number of
In Vitro Cultured Human HSPCs
Given the clinical relevance of HSPC transplantation in
humans, together with the effects of malonyl-CoA on
young and old mouse HSPCs in vitro and in vivo, we
tested if malonyl-CoA affects human HSPCs. Human
umbilical cord HSPCs (hHSPCs, CD34+/CD38) were
cultured for 5 days in vitro with or without the supple-
mentation of malonyl-CoA. By flow cytometry, we found
a significant increase in the percentage of hLin cells as
well as of all the human stem cell sub-populations
(CD34+/CD38 (HSPCs), lympho-myeloid progenitors
(hLMPPs), hMPPs and hHSCs) after malonyl-CoA expo-
sure (Figures 4A, 4B, and S4F), similar to the results ob-
tained in mouse HSPCs. A titration curve with three
different doses of malonyl-CoA further showed that
this increase appears to be dose dependent (Figure S4G).
















































































































































































Figure 4. Malonyl-CoA Leads to Increased
Proliferation of In Vitro Cultured Human
HSPCs
(A) Surface marker expression of human HSPCs
(Lin, CD34+, CD38), cultured in the presence
or absence of malonyl-CoA, was analyzed by
flow cytometry. Representative flow cytometry
plots showing the expression level of human
hLin, CD38/CD34+ (hHSPCs), lymphoid-
primed multipotent progenitors (hLMPPs),
multipotent progenitors (hMPPs) and he-
matopoietic stem cell (hHSC) markers.
(B) Quantification of the flow cytometry anal-
ysis. The total number of cells was normalized to
the median of the control condition. Culturing
of the Lin HSPCs in the presence of malonyl-
CoA significantly expanded the number of total
live cells as well as Lin cells. Further, malonyl-
CoA treatment induced a significant increase in
all the stem cell sub-populations (hHSPCs,
hLMPPs, hMPPs and hHSCs). Statistical analysis
was done including technical replicates by us-
ing nonparametric Mann-Whitney test (n = 6,
individual wells per condition, two independent
experiments, cells isolated from 2 3 2 pooled
human cord blood samples). *p < 0.05; **p <
0.01; ***p < 0.001. The increase in hHSPCs,
hHSCs, and hMPPs upon malonyl-CoA exposure
was also observed in a third independent
experiment with a similar experimental setup,
see Figure S4F.
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through malonyl-CoA increases the number of human
HSPC populations in vitro (Figure 4B).
DISCUSSION
The crucial role of metabolism in stem cell behavior in gen-
eral (Chandel et al., 2016; Ito and Suda, 2014) and in HSPCs
inparticular (Ito and Ito, 2018) has been established over the
past few years. The importance of glycolysis and mitochon-
drial activity for themost primitive HSPCs has led to various
approaches to interfere with these metabolic pathways to
promote HSPC expansion in vitro. The majority of those
studies used chemicals to enhance glycolysis (Guo et al.,
2018), block the fuel shuffling for oxidative phosphoryla-
tion (Takubo et al., 2013), or directly interfered with mito-
chondrial function, for instance by chemically uncoupling
the electron transport chain (Vannini et al., 2016), or knock-
ing out key mitochondrial players (Liu et al., 2015; Yu et al.,
2013). These studies showed that manipulating metabolism
is an approach to promote HSPC expansion. However,
blocking key metabolic enzymes or mitochondrial function
with chemicals might influence metabolism to a larger
extent and for longer than aimed for. In this study, we ex-
ploited the modulation of lipid metabolism by increasing
the levels of the endogenous metabolite malonyl-CoA,
which acts as a block of Cpt1a (Foster, 2012) and as a build-
ing block for de novo lipogenesis. Our data show that by
altering the levels of this single metabolite, HSPC behavior
is influenced in vitro and in vivo.We found an approximately
3-fold increased number of HSPCs after culturing with ma-
lonyl-CoA. These findings are in line with data from Ito
and colleagues (Ito et al., 2012), where an initial block of
FAO with the irreversible drug etomoxir led to a short-
term expansion of HSPCs. We show that the increased
number of phenotypically defined HSPCs upon malonyl-
CoA-induced in vitro expansion remained functional:
when transplanted in vivo, malonyl-CoA–treated LKS cells
showed ahigher blood reconstitutionpotential than control
LKS cells. These findings suggest that modulating the bal-
ance between FAO and de novo lipogenesis in vitro in LKS
cells led to an increase of functional HSPCs and did not
cause exhaustion of the stem cell pool, as seen with eto-
moxir. A possible explanation for these differences is that
we have used a short-term, reversible modulation instead
of an irreversible block, which might allow expansion of
HSPCs without a change in stem cell potential. LKS cells
exposed to malonyl-CoA even showed a slightly increased
performance in a secondary transplant, however, this did
not reach statistical significance.
Changes in gene expression were relatively small
after malonyl-CoA exposure, indicating no radical
change in cell identity, which is good when aiming for a
clinical application to enhance HSPC performance. Our
high-dimensional flow cytometry analysis suggests that
malonyl-CoA specifically enhances lymphoid progeni-
tors, corroborating the in vivo data showing increased
lymphoid potential upon reconstitution.Whether this in-
crease is due to a fate choice on the stem cell level or
whether malonyl-CoA enhances the proliferation or sur-
vival of already established lymphoid progenitors remains
to be determined.
Enhancing lymphoid reconstitution through metabolic
modulationmight be of clinical interest, as a rapid recovery
of immune function is crucial for patients undergoing
HSPC/BM transplantation (Copelan, 2006; Storek et al.,
2008). Furthermore, HSPCs are biased toward myeloid
cell production with aging, compromising immune system
function (Kovtonyuk et al., 2016). Our data with HSPCs
from old mice are very promising, showing that old HSPCs
remain responsive to this metabolic modulation. Although
the trends toward increased lymphoid-biased populations
were the same as in young HSPCs, old HSPCs showed a
greater variability upon malonyl-CoA exposure. Whether
this reflects increased heterogeneity in the aged HSPC
pool or whether the nonreactive HSPCs have irreversibly
lost their lymphoid potential remains to be determined.
In addition, myeloid progenitors (CMPs) were increased
upon malonyl-CoA exposure in cells from aged mice, indi-
cating that there might be a general proliferation or sur-
vival benefit.
Besides showing the power of metabolic modulation in
mouse HSPCs, this study also corroborates the similarities
in metabolism between different somatic stem cells. HSPCs
andNSPCs reside in completely different locations and their
progeny serve totally different functions; however, they are
both increasing proliferationuponaddition ofmalonyl-CoA
into the culture medium (this study and Knobloch et al.,
2017). As malonyl-CoA not only acts as a Cpt1 inhibitor,
but also serves as a substrate for de novo lipogenesis (Foster,
2012), this activation might be the consequence of
decreasing FAO and increasing de novo lipogenesis.
Strikingly, our data show that human cord blood HSPCs
react in a similar way to the exposure of malonyl-CoA,
opening an innovative avenue for treating cultured human
HSPCs. Modulating lipid metabolism might be interesting
in the context of therapeutic approaches where HSPCs
have to be functionally maintained in vitro, such as gene
therapy (Morgan et al., 2017). Whether malonyl-CoA
has similar effects on human HSCPs derived from adult
BM and if the age of the cells would influence the response
to malonyl-CoA remains to be explored. In summary,
we show that manipulation of a single metabolite, ma-
lonyl-CoA, is sufficient to alter mouse and human HSPC
behavior and enhances lymphoid potential in young and
old mouse HSPCs.
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EXPERIMENTAL PROCEDURES
Cell Sources and Preparation
All in vivo procedureswere carried out in compliancewith the Swiss
law after approval from the local authorities. C57Bl/6J (CD45.2)
and B6.SJL-PtprcaPepcb/BoyCrl (Ly5.1 or CD45.1) were purchased
fromCharles River Laboratories International. Murine HSPCs were
collected from freshly isolated BM. Human umbilical cord blood
was obtained with parent written informed consent from cords/
placentas of healthy full-term newborns.
Flow Cytometry
Mouse and human HSPCs were stained with fluorochrome-conju-
gated monoclonal antibodies listed under Supplemental Experi-
mentalProcedures. ThecellswereanalyzedontheLSRII,LSRFortessa
(Becton Dickinson), or FACS Symphony A5 (Becton Dickinson/BD
Biosciences). Cell sorting was performed by using FACS Aria II (Bec-
ton Dickinson) or MoFlo Astrios EQ (Beckman Coulter).
Cell Culture
Murine and human HSPCs were cultured with or without 5 to
200mM malonyl-CoA (CoALA Bioscience, MC01) for 5 to 7 days.
A half medium change was performed after 3 or 4 days. Eightymu-
rine HSCs (LKS CD150+CD48CD34 or +) were sorted into single
wells of 96-round bottom microwell plates (VWR, 163320) or
10,000 murine HSPCs (LinSca1+cKit+) or human HSPCs (Lin
CD34+CD38) were seeded per well of a 48-well plate (Falcon,
353078). NSPCs were isolated and cultured as previously described
(Knobloch et al., 2017).
RT-qPCR
A total of 25,000 LKS+, w/o LKS+, and Lin+ cells were sorted, RNA
isolated with RNeasy Micro Kit (Qiagen, 74,004), followed by
cDNA Synthesis (SuperScript IV, Invitrogen, 18091050). RT-qPCR
was performedwith Power SYBR-GreenMasterMix (Thermo Fisher
Scientific, 10658255). Primer sequences can be found under Sup-
plemental Experimental Procedures.
RNA Sequencing
RNA from the progeny of 10,000 initially cultured LKS cells was ex-
tracted, purified, and checked for integrity. Cluster generation was
performed and sequenced on the Illumina HiSeq 2500 using Tru-
Seq SBS Kit v4 reagents. Purified and filtered reads were aligned
againstMus musculus.GRCm38.86 genome and differential expres-
sion was computed. The 123 differentially expressed genes (with
an adjusted p value <0.1) were used for heatmap analysis using
iDEP 0.90. web-tool.
FAO Measurements
FAO measurements were performed as previously described (Kno-
bloch et al., 2017). Details can be found in the Supplemental
Experimental Procedures.
Transplantation Assay
For the primary transplantation, nine recipient mice (CD45.2)
per group were lethally irradiated 24 h before the i.v. injection
of LKS cells (CD45.1, Donor, n = 10) cultured with or without
100mM Mal-CoA for 7 days and mixed with 350,000 freshly iso-
lated competitor cells (CD45.1/2). For the secondary trans-
plants, 5 Mio. of BM cells of each primary recipient was isolated
27 weeks post transplantation and injected in a 1:1 mode with
freshly isolated competitor cells into lethally irradiated
CD45.2 mice. Blood sampling and analysis of the recipient
mice of the primary and secondary transplants were performed
at 4, 8, 12, 16, 20 and 24 weeks posttransplant followed by final
BM analysis.
Statistical Analysis
The following statistical tests were used: ordinary one-way
ANOVA followed by Holm-Sidak’s multiple comparison for
RT-PCR data (dCt level); Mann-Whitney test for surface marker
comparisons; two-way ANOVA (repeated measurement) followed
by Holm-Sidak’s for the transplantation data; and one-way
ANOVA followed by Holm-Sidak’s for titration curves. All statisti-
cal analyses were performed with Prism (GraphPad Software Inc).
In vitro experiments were confirmed with at least two indepen-
dent experiments. The key findings were confirmed in 3 to 6 in-
dependent experiments.
Data and Code Availability
Accession number for the RNA sequencing data:
The raw RNA sequencing data can be accessed via theGEO repos-
itory number GEO: GSE153201.
SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/
10.1016/j.stemcr.2020.07.021.
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Zamboni, N., Araúzo-Bravo, M.J., Kovacs, W.J., Karalay, Ö., Suter,
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